Showing results (71-80 of 111) with videos related to

Sort By:
Pageof 12
Annals of Neurology|February 1, 2011
Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumabMartin Gunnarsson, Clas Malmeström, Markus Axelsson, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 28, 2020
Inflammation-related plasma and CSF biomarkers for multiple sclerosisJesse Huang, Mohsen Khademi, Lars Fugger, et al.
Annals of Neurology|April 3, 2016
Rituximab versus fingolimod after natalizumab in multiple sclerosis patientsPeter Alping, Thomas Frisell, Lenka Novakova, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 14, 2011
A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosisCarolina Holmén, Fredrik Piehl, Jan Hillert, et al.
Therapeutic Advances in Neurological Disorders|September 19, 2025
Twenty years of natalizumab in multiple sclerosis: lessons learned and future outlookLuisa Klotz, Thomas Berger, Wallace J Brownlee, et al.
Journal of Neuroinflammation|December 13, 2024
Tyro3 and Gas6 are associated with white matter and myelin integrity in multiple sclerosisIgal Rosenstein, Lenka Novakova, Hlin Kvartsberg, et al.
European Journal of Neurology|May 25, 2024
Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort studySusanna Hallberg, Björn Evertsson, Ellen Lillvall, et al.
The Lancet. Neurology|July 12, 2011
Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trialPer Soelberg Sorensen, Jan Lycke, Juha-Pekka Erälinna, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|October 27, 2020
Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: an observational studyChristina Zhukovsky, Sofia Sandgren, Thomas Silfverberg, et al.
Neurology|May 22, 2020
Plasma neurofilament light levels are associated with risk of disability in multiple sclerosisAli Manouchehrinia, Pernilla Stridh, Mohsen Khademi, et al.
Pageof 12